NASDAQ
MDXG
Last Price
US $4.2
KEY FIGURES
MKT CAP
$0.6B
EPS
TTM
$0.04
EPS Growth (1Y)
14.29%
PEG
TTM
-
P/E
TTM
99.53x
P/S
TTM
1.75x
YIELD
-
GROWTH (5Y CAGR)
Revenue
Valuation
Financial
Performance
Cash flow to debt coverage
MiMedx Group, Inc. cash flow to debt ratio of 328.44% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.
Free cash flow growth
MiMedx Group, Inc.'s free cash flow has increased 13.11% from $64.52M last year to $72.97M, signaling increasing performance
Debt-to-equity ratio
MiMedx Group, Inc.'s debt to equity ratio is 0.01, which means that the company's assets are healthy financed, signaling financial stability.
Debt-to-equity trend
MiMedx Group, Inc.'s debt has decreased relative to shareholder equity from 0.13 last year to 0.01 today, signaling strengthened financials
Net debt to EBITDA
MiMedx Group, Inc. has a net cash position, so leverage is healthy.
Interest coverage
MiMedx Group, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Profit margin growth
MiMedx Group, Inc.'s profit margin has decreased (85.56%) in the last year from 12.16% to 1.76%, signaling decreasing performance
Current ratio
MiMedx Group, Inc.'s short-term assets of $277.47M exceed its short-term liabilities of $64.27M
Return on assets
MiMedx Group, Inc.'s return on assets of 2.22% is lower than the 5.00% threshold, indicating inefficient asset utilization
Return on equity
MiMedx Group, Inc.'s return on equity of 2.61%, is lower than 15.00%, indicating bad performance
Earnings quality
MiMedx Group, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation
Earnings stability
MiMedx Group, Inc. had positive net income in 3 out of 5 years, indicating stable and consistent earnings
Positive free cash flow
MiMedx Group, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Free cash flow yield
MiMedx Group, Inc. has a free cash flow yield of 11.72%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Earnings growth
MiMedx Group, Inc.'s yearly earnings has increased 14.52% since last year from $42.42M to $48.58M, signaling increasing performance
Revenue growth
MiMedx Group, Inc.'s yearly revenue has increased 19.99% since last year from $348.88M to $418.63M, signaling increasing performance
Return on invested capital
ROIC 1.94% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
3-year revenue CAGR
MiMedx Group, Inc.'s 3-year revenue CAGR of 16.05% is positive, indicating growing revenue over the past 3 years
Revenue consistency
MiMedx Group, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance
Return on equity consistency
MiMedx Group, Inc. had positive ROE in 3 out of 5 years, indicating consistent and reliable returns on equity
Cash Flow Valuation (DCF)
MiMedx Group, Inc. has insufficient data to evaluate this check.
Earnings yield (TTM)
MiMedx Group, Inc. has an earnings yield of 0.99%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings
EBITDA Valuation
MiMedx Group, Inc. is undervalued relative to its fair value price of 4.88 based on EBITDA multiple model
EV/EBITDA (FY)
MiMedx Group, Inc. has an EV/EBITDA ratio of 5.77x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
PEG ratio (TTM/FY)
MiMedx Group, Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.
Price-to-book ratio (FY)
MiMedx Group, Inc. has a price-to-book ratio of 2.92x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Price-to-sales ratio (TTM)
MiMedx Group, Inc. has a price-to-sales ratio of 1.78x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
2.61%
Return on equity
ROIC: 1.94%
Valuation History
105X
Price to Earnings
EV/EBITDA: 20.2X
Cash flow
Profit margin
11.02%
EBITDA
-
Cash flow
-
Cash Flow (DCF)
Fair Value
Market $4.2
—
Default assumptions
EBITDA Multiple
Fair Value
Market $4.2
16.19%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.